Impact of anatomic site of biliary tract tumour origin and conditional probability of survival (CS): results from 15 prospective advanced first-line clinical trials

Mairead Mcnamara, Andre Lopes, Harpreet Wasan, David Malka, David Goldstein, Jenny Shannon, Takuji Ojusaka, Jennifer J Knox, Dorothea Wagner, Thierry Andre, David Cunningham, Markus Moehler, Lars Henrik Jensen, Dieter Koeberle, Tanios Bekaii-Saab, John Bridgewater, Juan Valle

Research output: Contribution to conferenceAbstractpeer-review


Background: Inclusion of all patients (pts) with advanced biliary tract cancer (aBTC), irrespective of anatomic location, with assessment of overall survival (OS) in prospective trials, is debated. Additionally, outcome is typically described as estimated OS, but CS offers more relevant information once pts have survived for some time; this study assessed the impact of anatomic site of BTC origin and CS. Methods: Pts enrolled into 15 prospective first-line aBTC clinical trials were included. OS was analysed using Cox proportional hazard regression; CS and 95% confidence intervals (CIs) were calculated. Results: Overall, 1333 pts were included (Jan 97-Dec 13) with a median (med) age of 63 yrs (range 23-85); 46% male; 84% ECOG PS 0/1; 25% locally advanced (LA) stage, 72% metastatic (met), and 3% not reported (NR). Anatomic site of origin was gallbladder (GBC): 385 (29%), cholangiocarcinoma not specified (CCA-NS): 363 (27%), extrahepatic (EHC): 247 (19%), intrahepatic (IHC): 209 (16%), ampulla: 53 (4%) and 76 (6%) NR. Treatment was mono-chemotherapy: 310 (23%), cis/gem combination: 482 (36%), other combination: 520 (39%) and NR: 21 (2%). Med OS: 10.2 mths (95% CI 9.6-10.9). All sites, adjusted for treatment, had decreased risk of death vs GBC: EHC (p<.001), IHC (p<.002), CCA-NS (p<.003), ampulla (p=.003). This reduced risk vs GBC was maintained in those receiving cis/gem combination therapy in EHC (p<.001) and IHC (p<.001), but not in CCA-NS (p=.82) or ampulla (p=.96). Probabilities of surviving an additional yr given survival to 1 (n=552), 2 (n=170), 3 (n=53), and 4 (n=23) yrs post trial registration were 37%, 45%, 61%, and 63% respectively. For pts who survived 1 yr; those receiving combination therapy vs mono (p=.008), and those with IHC and CCA-NS vs GBC had better CS (both p<.05). Met stage vs LA was associated with shorter CS (p=.002) and ECOG PS and gender had no effect on CS (p>.05, p=.08 respectively). Conclusions: Pts with GBC have worse OS compared to other anatomic BTC sites. Inclusion of other BTC subtypes, at least, in prospective aBTC clinical trials is justified. Conditional probabilities allow adjusted prognosis prediction for survivors with aBTC.
Original languageEnglish
Publication statusPublished - 2019
EventESMO 2019 Congress: Translating science into better cancer patient care - Barcelona, Spain
Duration: 27 Sept 20191 Oct 2019


ConferenceESMO 2019 Congress
Internet address


  • Biliary tract cancer
  • Conditional probability of survival
  • Gallbladder cancer
  • Survival

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre


Dive into the research topics of 'Impact of anatomic site of biliary tract tumour origin and conditional probability of survival (CS): results from 15 prospective advanced first-line clinical trials'. Together they form a unique fingerprint.

Cite this